REGENXBIO, Inc. (RGNX)
7.43
+0.01
(+0.13%)
USD |
NASDAQ |
Oct 02, 16:00
7.54
+0.11
(+1.48%)
After-Hours: 20:00
REGENXBIO EPS Diluted (Quarterly) : 0.4283 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.4283 |
| March 31, 2026 | -1.718 |
| December 31, 2025 | -1.298 |
| September 30, 2025 | -1.198 |
| June 30, 2025 | -1.377 |
| March 31, 2025 | 0.1183 |
| December 31, 2024 | -1.033 |
| September 30, 2024 | -1.173 |
| June 30, 2024 | -1.047 |
| March 31, 2024 | -1.385 |
| December 31, 2023 | -1.429 |
| September 30, 2023 | -1.408 |
| June 30, 2023 | -1.655 |
| March 31, 2023 | -1.534 |
| December 31, 2022 | -1.384 |
| September 30, 2022 | -1.745 |
| June 30, 2022 | -1.582 |
| March 31, 2022 | -1.787 |
| December 31, 2021 | 6.670 |
| September 30, 2021 | -1.370 |
| June 30, 2021 | -1.356 |
| March 31, 2021 | -1.199 |
| December 31, 2020 | -1.236 |
| September 30, 2020 | 0.2261 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.9062 |
| March 31, 2020 | -1.079 |
| December 31, 2019 | -0.7171 |
| September 30, 2019 | -0.9394 |
| June 30, 2019 | -0.0397 |
| March 31, 2019 | -0.8862 |
| December 31, 2018 | 0.1106 |
| September 30, 2018 | -0.565 |
| June 30, 2018 | 0.30 |
| March 31, 2018 | 3.04 |
| December 31, 2017 | -0.51 |
| September 30, 2017 | -0.67 |
| June 30, 2017 | -0.47 |
| March 31, 2017 | -0.82 |
| December 31, 2016 | -0.7406 |
| September 30, 2016 | -0.6859 |
| June 30, 2016 | -0.5476 |
| March 31, 2016 | -0.409 |
| December 31, 2015 | -0.20 |
| September 30, 2015 | -1.525 |
| June 30, 2015 | -0.3456 |
| March 31, 2015 | -0.095 |
| March 31, 2014 | 0.0081 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 2.033 |
| United Therapeutics Corp. | 7.271 |
| Ardelyx, Inc. | -0.0674 |
| Biomea Fusion, Inc. | -0.1151 |
| RenovoRx, Inc. | -0.0616 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 22.71M |
| Revenue (Quarterly) | 108.02M |
| Total Expenses (Quarterly) | 85.31M |
| Enterprise Value | 547.16M |
| Gross Profit Margin (Quarterly) | 95.56% |
| Profit Margin (Quarterly) | 21.02% |
| Earnings Yield | -50.94% |
| Normalized Earnings Yield | -50.94 |